Literature DB >> 20858691

Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings.

Gulay Alper1, Kalliopi A Petropoulou, Charles R Fitz, Yeonhee Kim.   

Abstract

BACKGROUND: There is lack of reported magnetic resonance imaging (MRI) studies of idiopathic acute transverse myelitis (ATM) in children.
OBJECTIVE: To describe the imaging features of idiopathic ATM in children.
METHODS: We retrospectively analyzed the spinal MRI findings of children diagnosed with ATM. The anatomic regions, vertebral segmental length, gray or white matter involvement, cord expansion and gadolinium enhancement were examined.
RESULTS: A total of 27 children were diagnosed with isolated monophasic ATM with a mean follow-up of 5.2 years. Two children later diagnosed with neuromyelitis optica were excluded from the pediatric ATM cohort. None of the patients had a subsequent diagnosis of multiple sclerosis. The mean age of onset was 9.5 years (0.5-16.9 years). Spinal MRIs were abnormal in 21 (78%). The mean interval between symptom onset and the MRI was 1.7 days (0-19 days). Central cord hyperintensity involving gray matter was seen in all patients. A majority (67%) of the patients demonstrated long segment lesions with a mean segment length of 6.4.
CONCLUSIONS: We conclude that central cord inflammation extending over three or more segments is the most common finding of idiopathic monophasic transverse myelitis in children. The risk of multiple sclerosis in children who experience isolated transverse myelitis as a first demyelinating event is low.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858691      PMCID: PMC3022414          DOI: 10.1177/1352458510381393

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  28 in total

1.  Gadolinium-MRI in acute transverse myelopathy.

Authors:  K A Sanders; A G Khandji; J P Mohr
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

2.  Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI.

Authors:  K Bashir; J N Whitaker
Journal:  Mult Scler       Date:  2000-10       Impact factor: 6.312

Review 3.  Proposed diagnostic criteria and nosology of acute transverse myelitis.

Authors: 
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

4.  Prospective study of patients presenting with acute partial transverse myelopathy.

Authors:  C Cordonnier; J de Seze; G Breteau; D Ferriby; E Michelin; T Stojkovic; J P Pruvo; P Vermersch
Journal:  J Neurol       Date:  2003-12       Impact factor: 4.849

5.  Acute transverse myelitis in children: clinical course and prognostic factors.

Authors:  Pierre Defresne; Henri Hollenberg; Béatrice Husson; Brahim Tabarki; Pierre Landrieu; Gilbert Huault; Marc Tardieu; Guillaume Sébire
Journal:  J Child Neurol       Date:  2003-06       Impact factor: 1.987

6.  First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability.

Authors:  Yann Mikaeloff; Samy Suissa; Louis Vallée; Catherine Lubetzki; Gérard Ponsot; Christian Confavreux; Marc Tardieu
Journal:  J Pediatr       Date:  2004-02       Impact factor: 4.406

7.  Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features.

Authors:  Gulay Alper; Rock Heyman; Li Wang
Journal:  Dev Med Child Neurol       Date:  2008-10-24       Impact factor: 5.449

8.  Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients.

Authors:  Michael Harzheim; Uwe Schlegel; Horst Urbach; Thomas Klockgether; Stephan Schmidt
Journal:  J Neurol Sci       Date:  2004-02-15       Impact factor: 3.181

Review 9.  Determinants of prognosis of acute transverse myelitis in children.

Authors:  Reiko Miyazawa; Yuka Ikeuchi; Takeshi Tomomasa; Hideo Ushiku; Tetsushi Ogawa; Akihiro Morikawa
Journal:  Pediatr Int       Date:  2003-10       Impact factor: 1.524

Review 10.  MRI findings in acute idiopathic transverse myelopathy in children.

Authors:  Savvas Andronikou; Glenda Albuquerque-Jonathan; Jo Wilmshurst; Richard Hewlett
Journal:  Pediatr Radiol       Date:  2003-07-18
View more
  8 in total

Review 1.  Acquired pathology of the pediatric spine and spinal cord.

Authors:  Susan Palasis; Laura L Hayes
Journal:  Pediatr Radiol       Date:  2015-09-07

Review 2.  Longitudinally extensive myelopathy in children.

Authors:  Danielle Eckart Sorte; Andrea Poretti; Scott D Newsome; Eugen Boltshauser; Thierry A G M Huisman; Izlem Izbudak
Journal:  Pediatr Radiol       Date:  2015-01-31

3.  Neurological and functional recovery in acute transverse myelitis patients with inpatient rehabilitation and magnetic resonance imaging correlates.

Authors:  A Gupta; S N Kumar; A B Taly
Journal:  Spinal Cord       Date:  2016-03-01       Impact factor: 2.772

4.  Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis.

Authors:  Katharina Wolf; Thomas Schmitt-Mechelke; Spyridon Kollias; Armin Curt
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

Review 5.  Pain and spinal cord imaging measures in children with demyelinating disease.

Authors:  Nadia Barakat; Mark P Gorman; Leslie Benson; Lino Becerra; David Borsook
Journal:  Neuroimage Clin       Date:  2015-09-06       Impact factor: 4.881

6.  Longitudinal extensive transverse myelitis (LETM) in children: A twenty-year study from Oman.

Authors:  Roshan Koul; Amna M Alfutaisi; Renjith Mani; Rana A Abdel Rahim; Dilip K Sankhla; Faisal M Al Azri
Journal:  Neurosciences (Riyadh)       Date:  2017-04       Impact factor: 0.906

Review 7.  Acute Transverse Myelitis in Children, Literature Review.

Authors:  Azita Tavasoli; Aidin Tabrizi
Journal:  Iran J Child Neurol       Date:  2018

Review 8.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.